(Q28252893)

2

0 references

Fang Liu

3

0 references

Cathy Stevens

4

0 references

Amy Q Wang

5

0 references

Wei Zeng

6

0 references

Li Chen

7

0 references

Karen Snyder

8

0 references

Deborah Hilliard

9

0 references

Michael Tanen

10

0 references

Wesley Tanaka

11

0 references

Alan G Meehan

12

0 references

Kenneth Lasseter

13

0 references

Stacy Dilzer

14

0 references

Robert Blum

15

0 references

John A Wagner

The Journal of Clinical Pharmacology

16

0 references

language of work or name

English

0 references

publication date

August 2006

0 references

published in

0 references

volume

46

0 references

issue

8

0 references

page(s)

876-86

0 references

cites work

Gut peptides and type 2 diabetes mellitus treatment

1 reference

https://api.crossref.org/works/10.1177%2F0091270006289850

Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006289850

The glucagon-like peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006289850

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006289850

Therapeutic strategies based on glucagon-like peptide 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006289850

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006289850

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006289850

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006289850

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006289850

(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006289850

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006289850

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006289850

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006289850

Determination of MK-0431 in human plasma using high turbulence liquid chromatography online extraction and tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006289850

A role for glucagon-like peptide-1 in the central regulation of feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006289850

Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006289850